Hyperprogression disease induced by Sintilimab combined with Oxaliplatin and S-1 after surgery: a case report and literature review
ObjectiveTo investigate the risk factors, underlying mechanisms, and preventive strategies associated with hyperprogressive disease (HPD) induced by immunotherapy.MethodsWe analyzed the clinical data of a patient who developed HPD following palliative gastrectomy and received a combination therapy o...
Saved in:
| Main Authors: | Yaoqi Li, You Wang, Rui Shen, Weijun Liu, Chenglou Zhu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1494007/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of oxaliplatin and capecitabine in combination with sintilimab as first-line treatment for HER2-negative advanced gastric cancer
by: ZHANG Xiaorui, SHAN Haixia, ZHU Zhengqiu
Published: (2025-01-01) -
Short-term efficacy and safety of sintilimab combined with oxaliplatin and capecitabine as neoadjuvant therapy for locally advanced gastric cancer
by: ZHANG Shuai, LIU Liangliang, HUANG Di, SHENG Ru, DU Xuetao, LI Shuguang, HU Nan, ZHAO Yifeng
Published: (2025-01-01) -
Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report
by: Yao Zhang, et al.
Published: (2024-12-01) -
A case report: interstitial pneumonia following treatment of gastric cancer with sintilimab in combination with S-1
by: Pei Zhu, et al.
Published: (2025-02-01) -
Stevens–Johnson syndrome induced by Sintilimab: a case report and literature review
by: Huan Kuang, et al.
Published: (2025-05-01)